BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32451408)

  • 1. SATB1 as oncogenic driver and potential therapeutic target in head & neck squamous cell carcinoma (HNSCC).
    Panchal O; Wichmann G; Grenman R; Eckhardt L; Kunz-Schughart LA; Franke H; Dietz A; Aigner A
    Sci Rep; 2020 May; 10(1):8615. PubMed ID: 32451408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple effects of the special AT-rich binding protein 1 (SATB1) in colon carcinoma.
    Frömberg A; Rabe M; Aigner A
    Int J Cancer; 2014 Dec; 135(11):2537-46. PubMed ID: 24729451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells.
    Frömberg A; Rabe M; Oppermann H; Gaunitz F; Aigner A
    BMC Cancer; 2017 Jan; 17(1):3. PubMed ID: 28049521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA LINC00491 accelerates head and neck squamous cell carcinoma progression through regulating miR-508-3p/SATB1 axis and activating Wnt signaling pathway.
    Cui D; Li Z; Wei C; Zhang Q; Xiao C
    Cytokine; 2024 Mar; 175():156444. PubMed ID: 38150791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of SATB1 promotes the growth and metastasis of colorectal cancer.
    Zhang Y; Tian X; Ji H; Guan X; Xu W; Dong B; Zhao M; Wei M; Ye C; Sun Y; Yuan X; Yang C; Hao C
    PLoS One; 2014; 9(6):e100413. PubMed ID: 24971456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Trop2 blockade enhances the therapeutic efficacy of ErbB3 inhibition in head and neck squamous cell carcinoma.
    Redlich N; Robinson AM; Nickel KP; Stein AP; Wheeler DL; Adkins DR; Uppaluri R; Kimple RJ; Van Tine BA; Michel LS
    Cell Death Dis; 2018 Jan; 9(1):5. PubMed ID: 29305574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.
    Wang D; Qian G; Zhang H; Magliocca KR; Nannapaneni S; Amin AR; Rossi M; Patel M; El-Deiry M; Wadsworth JT; Chen Z; Khuri FR; Shin DM; Saba NF; Chen ZG
    Clin Cancer Res; 2017 Feb; 23(3):677-686. PubMed ID: 27358485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR aptamer-conjugated liposome-polycation-DNA complex for targeted delivery of SATB1 small interfering RNA to choriocarcinoma cells.
    Dong J; Cao Y; Shen H; Ma Q; Mao S; Li S; Sun J
    Biomed Pharmacother; 2018 Nov; 107():849-859. PubMed ID: 30142547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LncRNA LINC00460 promotes EMT in head and neck squamous cell carcinoma by facilitating peroxiredoxin-1 into the nucleus.
    Jiang Y; Cao W; Wu K; Qin X; Wang X; Li Y; Yu B; Zhang Z; Wang X; Yan M; Xu Q; Zhang J; Chen W
    J Exp Clin Cancer Res; 2019 Aug; 38(1):365. PubMed ID: 31429766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer.
    Novoplansky O; Fury M; Prasad M; Yegodayev K; Zorea J; Cohen L; Pelossof R; Cohen L; Katabi N; Cecchi F; Joshua BZ; Popovtzer A; Baselga J; Scaltriti M; Elkabets M
    Int J Cancer; 2019 Aug; 145(3):748-762. PubMed ID: 30694565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic regulation of long noncoding RNA UCA1 by SATB1 in breast cancer.
    Lee JJ; Kim M; Kim HP
    BMB Rep; 2016 Oct; 49(10):578-583. PubMed ID: 27697109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low doses of methylnaltrexone inhibits head and neck squamous cell carcinoma growth in vitro and in vivo by acting on the mu-opioid receptor.
    Gorur A; Patiño M; Shi T; Corrales G; Takahashi H; Rangel R; Gleber-Netto FO; Pickering C; Myers JN; Cata JP
    J Cell Physiol; 2021 Nov; 236(11):7698-7710. PubMed ID: 34038587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
    Yun M; Choi AJ; Lee YC; Kong M; Sung JY; Kim SS; Eun YG
    J Exp Clin Cancer Res; 2018 Oct; 37(1):264. PubMed ID: 30376862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuregulin Signaling Is a Mechanism of Therapeutic Resistance in Head and Neck Squamous Cell Carcinoma.
    Baro M; Lopez Sambrooks C; Burtness BA; Lemmon MA; Contessa JN
    Mol Cancer Ther; 2019 Nov; 18(11):2124-2134. PubMed ID: 31387891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer.
    Selinger CI; Cooper WA; Al-Sohaily S; Mladenova DN; Pangon L; Kennedy CW; McCaughan BC; Stirzaker C; Kohonen-Corish MR
    J Thorac Oncol; 2011 Jul; 6(7):1179-89. PubMed ID: 21597389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heregulin and HER3 are prognostic biomarkers in oropharyngeal squamous cell carcinoma.
    Qian G; Jiang N; Wang D; Newman S; Kim S; Chen Z; Garcia G; MacBeath G; Shin DM; Khuri FR; Chen ZG; Saba NF
    Cancer; 2015 Oct; 121(20):3600-11. PubMed ID: 26195293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global Proteomics-based Identification and Validation of Thymosin Beta-4 X-Linked as a Prognostic Marker for Head and Neck Squamous Cell Carcinoma.
    Chi LH; Chang WM; Chang YC; Chan YC; Tai CC; Leung KW; Chen CL; Wu AT; Lai TC; Li YJ; Hsiao M
    Sci Rep; 2017 Aug; 7(1):9031. PubMed ID: 28831179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
    Radhakrishnan A; Nanjappa V; Raja R; Sathe G; Puttamallesh VN; Jain AP; Pinto SM; Balaji SA; Chavan S; Sahasrabuddhe NA; Mathur PP; Kumar MM; Prasad TS; Santosh V; Sukumar G; Califano JA; Rangarajan A; Sidransky D; Pandey A; Gowda H; Chatterjee A
    Sci Rep; 2016 Oct; 6():36132. PubMed ID: 27796319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of EZH2 inhibits epithelial‑mesenchymal transition in head and neck squamous cell carcinoma via regulating the STAT3/VEGFR2 axis.
    Zhao M; Hu X; Xu Y; Wu C; Chen J; Ren Y; Kong L; Sun S; Zhang L; Jin R; Zhou X
    Int J Oncol; 2019 Nov; 55(5):1165-1175. PubMed ID: 31545422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting mTOR by CZ415 Inhibits Head and Neck Squamous Cell Carcinoma Cells.
    Xie J; Li Q; Ding X; Gao Y
    Cell Physiol Biochem; 2018; 46(2):676-686. PubMed ID: 29621758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.